Skip to main content
SpringerLink
Log in

Valsartan/Hydrochlorothiazide

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Valsartan/hydrochlorothiazide (HCTZ) combines an angiotensin II AT1 receptor blocker with a thiazide diuretic to produce additive blood pressure reductions without major effects on heart rate.

  • ▴ HCTZ did not significantly alter valsartan pharmacokinetics; during combination therapy, HCTZ pharmacokinetics differed from those seen with HCTZ monotherapy.

  • ▴ In clinical trials in patients with essential hypertension, adding HCTZ 12.5 or 25 mg/day to valsartan 80 mg/day resulted in a greater blood pressure reduction than increasing the valsartan dosage from 80 to 160 mg/day.

  • ▴ The valsartan/HCTZ combination was generally more effective than either drug given alone. Efficacy of the combination was maintained during up to 3 years of treatment.

  • ▴ Valsartan/HCTZ was well tolerated in both short and long term trials. The most common adverse events were dizziness, headache and fatigue. The overall incidence of adverse events with the combination was similar to that with placebo. HCTZ-induced hypokalaemia was less common during combination therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997 Aug; 54(2): 299–311

    Article  PubMed  CAS  Google Scholar 

  2. Close P. Expert report on the clinical documentation. Co-Diovan™ 80/12.5 mg film-coated tablets (valsartan/hydrochlorothiazide, CGP 63170). 6 March, 1997. Novartis Pharma AG. Basel, Switzerland

    Google Scholar 

  3. Sica D. Fixed-dose combination antihypertensive drugs: do they have a role in rational therapy? Drugs 1994; 48(1): 16–24

    Article  PubMed  CAS  Google Scholar 

  4. Webb RL, Navarette AE, Davis S. Effects of valsartan and hydrochlorothiazide alone and in combination on blood pressure and heart rate in conscious-telemetered spontaneously hypertensive rats. Am J Hypertens 1998; 11: 59–65

    Article  PubMed  CAS  Google Scholar 

  5. Fujimura Y. Antihypertensive effect of a combination of valsartan and hydrochlorothiazide, nifedipine or propranolol in spontaneously hypertensive rats [in Japanese]. Yakuri to Chiryo 1995 Dec; 23(12): 87–93

    Google Scholar 

  6. Novartis Pharma AG. Data on file. Novartis Pharma AG, Basel, Switzerland

  7. Hall WD, Montoro R, Littlejohn T, et al. Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension. Clin Drug Invest 1998 Sep; 16(3): 203–10

    Article  CAS  Google Scholar 

  8. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861–6

    Article  PubMed  CAS  Google Scholar 

  9. Chrysant SG, Wombolt DG, Feliciano N, et al. Long-term efficacy, safety and tolerability of valsartan and hydrochlorothiazide in patients with essential hypertension. Curr Ther 1998 Nov; 59(11): 762–7

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Heather D. Langtry & Karen J. McClellan

Authors
  1. Heather D. Langtry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen J. McClellan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Langtry, H.D., McClellan, K.J. Valsartan/Hydrochlorothiazide. Drugs 57, 751–755 (1999). https://doi.org/10.2165/00003495-199957050-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199957050-00008

Keywords

Search

Navigation